10 résultats
BACKGROUND OF THE DISCLOSURE
The present disclosure relates generally to modulating inflammation using progesterone metabolites. More particularly, the present disclosure relates the use of two progesterone metabolites, 6.beta.-hydroxyprogesterone (6.beta.-OHP) and 16.alpha.-hydroxyprogesterone
TECHNICAL FIELD
This invention provides methods for treating inflammatory conditions, including but not limited to, inflammatory bowel disease (ulcerative colitis, Crohn's disease, and proctitis), other noninfectious, inflammatory conditions of the GI tract (microscopic colitis, allergic
FIELD
This disclosure relates to progesterone derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation such as those resulting from traumatic brain injury or stroke.
BACKGROUND
Brain injuries, including
FIELD
This disclosure relates to progesterone phosphate derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation such as those resulting from traumatic brain injury or stroke.
BACKGROUND
Brain injuries,
FIELD
This disclosure relates to progesterone phophate derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation such as those resulting from traumatic brain injury or stroke.
BACKGROUND
Brain injuries,
BACKGROUND OF THE INVENTION
The present invention relates to a diagnostic test for testing the susceptibility of individuals to inflammatory diseases such as rheumatoid arthritis with therapeutic agents directed at the central nervous system (CNS), designed to by-pass the CNS defect.
SUMMARY OF THE
BACKGROUND OF THE INVENTION
The physiology of many organs in mammals is regulated by hormones. These hormones include steroid hormones, thyroid hormones, metabolites of vitamins, such as all trans retinoic acid, 9-cis retinoic acid, vitamin D and its metabolite 1,25 dihydroxyvitamin D3. These
TECHNICAL FIELD
This invention generally relates to genetic therapy and molecular and cellular biology. In alternative embodiments, provided are engineered B lymphocytes modified to express one or several different types of microRNAs (miRs), where in alternative embodiments the lymphocytes contain
BACKGROUND OF THE INVENTION
This invention relates to isolated and purified proteins, such as calreticulin and mimetics of calreticulin, for a novel use of modulating hormone responsiveness. These proteins are useful in gene therapy and in manufacturing pharmaceuticals for treating a variety of
FIELD OF THE INVENTION
The present invention relates to therapeutics, and more especially NSAID and/or cannabis based therapeutics for use in treating those known to have or be at increased risk of endometriosis and other ailments.
BACKGROUND OF THE INVENTION
Endometriosis is a common gynecological